Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | CNR1 | P21554 | 4/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18551018 | 0.84 | — | — | |
| SCHEMBL18726620 | 0.83 | RAB9A (0.34) | RAB9ACNR2CNR1PPARGPPARD | |
| SCHEMBL20663294 | 0.82 | — | — | |
| SCHEMBL15293403 | 0.81 | CRBN (0.41) | CRBNTAS2R38 | |
| SCHEMBL19983010 | 0.80 | CRBN (0.33) | CRBNTAS2R38 | |
| SCHEMBL20442275 | 0.79 | RAB9A (0.33) | RAB9ACNR2CNR1PPARGPPARD | |
| SCHEMBL27382484 | 0.76 | CRBN (0.33) | CRBNTAS2R38 | |
| SCHEMBL18404292 | 0.76 | CNR2 (0.33) | RAB9ACNR2CNR1PPARGPPARD | |
| SCHEMBL13847434 | 0.75 | MAPT (0.33) | RAB9ACNR2CNR1PPARGPPARD | |
| SCHEMBL24247970 | 0.74 | CNR2 (0.33) | RAB9ACNR2CNR1PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023031775-A1 | COMPOSITIONS FOR PREVENTING OR TREATING CHARCOT-MARIE-TOOTH DISEASE (CMT) | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-03-09 | — | — | WO | disclosed |
| US-20170008950-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC | 2017-01-12 | — | — | US | disclosed |
| US-20160024226-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC | 2016-01-28 | — | — | US | disclosed |
| US-20130112106-A1 | ENVIRONMENTALLY FRIENDLY CORROSION INHIBITOR | APERGY ESP SYSTEMS, LLC | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024226-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, FCGR2A, VSIG8 | RAB9A 3740/4885CNR2 2715/4885CNR1 2035/4885 |
| US-20170008950-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, SCLY, FCGR2A | RAB9A 3370/4885CNR2 4510/4885CNR1 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.